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Endocytic trafﬁckingSpongiform neurodegeneration is characterized by the appearance of vacuoles throughout the central
nervous system. It has many potential causes, but the underlying cellular mechanisms are not well
understood. Mice lacking the E3 ubiquitin ligase Mahogunin Ring Finger-1 (MGRN1) develop age-dependent
spongiform encephalopathy. We identiﬁed an interaction between a “PSAP” motif in MGRN1 and the
ubiquitin E2 variant (UEV) domain of TSG101, a component of the endosomal sorting complex required for
transport I (ESCRT-I), and demonstrate that MGRN1 multimonoubiquitinates TSG101. We examined the in
vivo consequences of loss of MGRN1 on TSG101 expression and function in the mouse brain. The pattern of
TSG101 ubiquitination differed in the brains of wild-type mice and Mgrn1 null mutant mice: at 1 month of
age, null mutant mice had less ubiquitinated TSG101, while in adults, mutant mice had more ubiquitinated,
insoluble TSG101 than wild-type mice. There was an associated increase in epidermal growth factor receptor
(EGFR) levels in mutant brains. These results suggest that loss of MGRN1 promotes ubiquitination of TSG101
by other E3s and may prevent its disassociation from endosomal membranes or cause it to form insoluble
aggregates. Our data implicate loss of normal TSG101 function in endo-lysosomal trafﬁcking in the
pathogenesis of spongiform neurodegeneration in Mgrn1 null mutant mice.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Spongiform encephalopathy, where vacuoles develop throughout
the central nervous system (CNS), can be caused by infection with the
conformationally altered form of the cellular prion protein (PrPSc),
retroviruses including human immunodeﬁciency virus (HIV), murine
leukemia virus (MuLV) or maedi-visna virus (MVV), and coronavirus
[1–4]. In humans, spongiform changes are also observed in Alzhei-
mer's disease, diffuse Lewy body disease, Niemann–Pick disease
(caused by lysosomal storage defects), Leigh disease (caused by
mitochondrial dysfunction) and Canavan disease (caused by aspar-
toacylase deﬁciency) [5–7]. Inherited spongiform encephalopathies
develop in mutant mice homozygous for null alleles of Mahogunin
Ring Finger-1 (Mgrn1), Attractin (Atrn), superoxide dismutase 2 (Sod2),
Fig4, Vac14 and the Kir4.1 potassium channel subunit [8-15]. These
genetic models provide an opportunity to gain insight into the
mechanisms that underlie vacuolar changes in the CNS through the
identiﬁcation of the cellular role(s) of themutated proteins. While the
function of the proteins encoded by all of these genes is not known,e for Biomedical Sciences, 1520
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ll rights reserved.several are known to affect mitochondrial function or endo-lysosomal
trafﬁcking.
The endo-lysosomal pathway plays a critical role in a variety of
cellular activities including nutrient intake, signal transduction, and
receptor down-regulation, recycling and degradation. Defects in
endocytic trafﬁcking are associated with numerous diseases including
pigmentation, bleeding and neurodegenerative disorders [9,16-24].
Transmembrane proteins are primarily internalized into cells via
clathrin-mediated endocytosis, then delivered into early endosomes
(EEs) where they are clustered and sorted into intraluminal vesicles to
formmultivesicular bodies (MVBs). WhenMVBs fuse with lysosomes,
these vesicles and their contents are degraded by lysosomal enzymes.
Sorting into MVBs is a critical regulatory step for many proteins and
requires ubiquitination at several steps along the way [25]. Ubiquiti-
nation is a multistep process in which the small polypeptide ubiquitin
is activated in anATP-dependentmanner and then covalently attached
to target proteins through the concerted actions of ubiquitin activating
(E1), conjugating (E2) and ligase (E3) proteins [26]. Ubiquitination is a
sorting signal for many processes, such as trafﬁcking toward the
lysosome from many cellular compartments including the plasma
membrane (where it promotes internalization), Golgi (where it can
divert proteins to endosomes) and MVBs [reviewed by [27]].
Protein sorting into MVBs is regulated by endosomal sorting
complexes required for transport (ESCRT)-I, II and III. The sorting
process is initiated by the recruitment of hepatocyte growth factor
(HGF)-regulated tyrosine kinase substrate (HRS, also commonly
referred to as ESCRT-0) to the endosomal membrane through its
FYVE domain, which binds to phosphatidylinositol-3-phosphate
Fig. 1.MGRN1 associates with TSG101. (A) Schematic of TSG101 and MGRN1 proteins.
Regions of each protein found to interact with the other in yeast two-hybrid assays are
indicated by dashed lines. UEV: ubiquitin E2 variant domain; PRD: proline rich
domain; CC: coiled-coil domain; SB: steadiness box domain; RF: C3HC4 ring ﬁnger
domain. The position of late-viral P[S/T]AP domains in TSG101 and MGRN1 are also
indicated. (B) MGRN1 associates with TSG101. IP of lysates from untransfected
HEK293T cells for TSG101 (left panel) or MGRN1 (right panel) followed by IB for
MGRN1 (left panel) or TSG101 (right panel) conﬁrmed association of the endogenous
proteins. Clean-blot detection reagent was used in lieu of secondary antibody for
TSG101 IB of MGRN1 IP products to eliminate the heavy chain IgG band that otherwise
obscures the TSG101 signal.
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ubiquitin-interacting motif (UIM), while a C-terminal “LIEL” sequence
binds to clathrin. HRS recruits ESCRT-I to the sorting site via a PSAP
motif, which binds to the ubiquitin E2 variant (UEV) domain of the
ESCRT-I component TSG101. Ubiquitinated cargo are recognized by the
UEV domain of TSG101 and the Npl4 zincﬁnger (N2F) domain of VPS36
in ESCRT-II. Cargo proteins are clustered by the ESCRT-III complex and
their ubiquitin moieties removed by the deubiquitinating enzyme
DOA4. Cargo are then sorted to the inner vesicles ofMVBs and theESCRT
complexes are disassembled by the AAA-type ATPase VPS4 [28-30].
Ubiquitination and the ESCRT machinery are also involved in retroviral
budding [31,32]. UbiquitinatedGAGproteins ofmany viruses, including
HIV, associate with TSG101 to recruit it and the ESCRTmachinery to the
plasmamembrane,where the sameprocesses that give rise toMVBs are
used to bud virus particles out of the cell [33-36].
Mice lacking the E3 ubiquitin ligase Mahogunin Ring Finger-1
(MGRN1) develop progressive, widespread spongiform neurode-
generation of the CNS that ﬁrst becomes apparent between 9 and
12 months of age [11]. This phenotype is preceded by mitochondrial
dysfunction and elevated oxidative stress [37].Mgrn1null mutantmice
also have a defect in pigment-type switching that prevents them from
producing yellow pigment [38], and aberrant patterning of the left–
right body axis during development that causes lethal congenital heart
defects in ∼50% of animals [39]. As an E3 ligase, MGRN1 may target a
wide variety of proteins for ubiquitination to account for the broad
spectrum of phenotypes observed in null mutants, or it may target a
small number of proteins that have essential roles inmultiple cell types
to exert its pleiotropic effects. Here, we conﬁrm a previous report that
MGRN1 associates with and ubiquitinates TSG101, a component of
ESCRT-I [40], and extend the analysis by examining the in vivo
consequences of loss of MGRN1. We demonstrate that ubiquitination
of TSG101 in themousebrain is regulated in part byMGRN1and that its
solubility andpattern of ubiquitination changewith age in normalmice
and differs between wild-type and Mgrn1 null mutant mice. We
propose a model in which endocytic trafﬁcking in general, and TSG101
in particular, plays a central role in the pathogenesis of spongiform
encephalopathy inMgrn1 null mutant mice.
2. Materials and methods
2.1. Mice
Mgrn1md-nc (null) mutant mice were originally obtained as frozen
heterozygous F1 embryos (C3H×101 strains) from Harwell Mamma-
lian Genetics Unit (Harwell, UK) and have been maintained by
brother-sister inbreeding of homozygotes to heterozygotes for over
21 generations. A line of coisogenic wild-type control mice was
generated by intercrossing inbred (N21 generations) Mgrn1md-nc/+
mice to obtain Mgrn1+/+ animals; this line has also been maintained
by brother-sister inbreeding, with 3–4 generations separating them
from theMgrn1md-nc allele-carrying line. C3H/HeJ mice were obtained
from the Jackson Laboratory (Bar Harbor, ME) and maintained at
Cornell University by brother-sister inbreeding for up to 6 genera-
tions. Mice were maintained under standard conditions in the AALAC
certiﬁed Transgenic Mouse Core Facility at Cornell University. All
experiments involving mice adhered to the Public Health Service
Policy on Humane Care and Use of Laboratory Animals and were
approved by Cornell University IACUC.
2.2. Protein interaction and ubiquitination studies
Yeast two-hybrid assays were performed using the ProQuest Two-
Hybrid System with Gateway technology (Invitrogen, Carlsbad CA).
The cDNA encoding the C-terminus of MGRN1 isoform I (encoding the
region downstream of the RING domain, amino acids 316–532; Fig. 1)
was fused to the GAL4 DNA binding domain (DB) in the pDEST32 baitvector and used to screen a mouse brain cDNA library (Invitrogen
#11298-015). Plasmids encoding proteins that interacted with
MGRN1 were isolated using a yeast plasmid isolation kit (Clontech,
Mountain View, CA) and sequenced at the Cornell University
Sequencing Core Facility. Tsg101 expression constructs were provided
by Dr. Kay-Uwe Wagner, University of Nebraska Medical Center. HA-
tagged wild-type ubiquitin was provided by Pengbo Zhou, Weill
Medical College. GFP-tagged ubiquitin K0 (all lysine residues mutated
to arginines, rendering it incapable of forming polyubiquitin chains)
was obtained from Nico Dantuma via Addgene (plasmid 11934) [41].
Full-length MGRN1 isoform I was ampliﬁed by RT-PCR from C3H/
HeJ mouse brain RNA using primers: GGGGACAAGTTTGTAC-
AAAAAAGCAGGCTCCGGCTGGCCGGTAGAAAC and GGGGACCACTTT-
GTACAAGAAAGCTGGGTACTATACCAACAGAGCACGAC. PCR products
were cloned using the Gateway system into the pEGFP-N1 vector
(to express C-terminal GFP-tagged MGRN1) (Clontech). Isoform I was
also ampliﬁed using primers CACCATGGGCTCCATCATGA and
TTACTCCTCTATACCAACAG and cloned into pKH3 vector (to express
N-terminal triple hemagglutinin (HA)-tagged MGRN1). The vectors
were ﬁrst converted to be Gateway compatible using the Gateway
Vector Conversion System (Invitrogen). A SalI/BamHI fragment of
IMAGE clone 6401088, which encodes full-length MGRN2 (RNF157),
was puriﬁed and ligated into Gateway modiﬁed pEGFP-N1 to create a
mammalian expression construct for MGRN2 where its ﬁnal 3 amino
acids are replaced by GFP.
MGRN1 isoform I in pEGFP-N1 was used as template for site-
directed mutagenesis using QuickChange Site Directed Mutagenesis
kit (Stratagene). Cysteine residues at positions 278 and 281 were
mutated to alanine residues to generate MGRN1(AVVA)-GFP using
forward primer GACAACAGCAGTGAGGCTGTGGTGGCCCTGTCAGA-
CCTGCG and reverse primer CTGTTGTCGTCACTCCGACACCACCGGGA-
CAGTCTGGACGC. This CVVC to AVVA mutation has previously been
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motif at amino acid position 384–387 (isoform I) was mutated to
ASAA (subsequently referred to as MGRN1(ASAA)) using forward
primer CCCCGGCTA-TCGCATCAGCTGCCCTCTATGAG and reverse
primer GATGGGCTCATAGCCAGCTGCGATACTGTCAGAACTAG.
Plasmid DNA or siRNA against Mgrn1 (sense: GAACUCGG-
CCUAUCGCUACUU, antisense: PGUAGCGAUAGGCCGAGUUCUU,
corresponding to amino acids 57–75 of human MGRN1) or a
scrambled control siRNA (sense:GUACCGCACCGCUAGUCAU, antisense:
AUGACUAGCGGUGCGGUAC) were transfected into Human Embryonic
Kidney (HEK293T) cells for transient overexpression. Fig. S1 in the
supplementary material demonstrates the efﬁciency of MGRN1 knock-
down. For ubiquitination assays, some cells were treated with 50 μM of
the proteasome inhibitor MG132 for 2–4 h before lysis. Cells were
harvested in lysis buffer containing Complete protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN) 24–48 h after transfection,
frozen and thawed 3 times, then used for TA puriﬁcation or
coimmunoprecipitation (coIP) using Protein G IP Kit (Sigma-Aldrich
Corp., St. Louis, MO) or GrabIt IP kit (Calbiochem, Gibbstown, NJ)
according to manufacturer's instructions. Mouse brains were homoge-
nized in Cytobuster buffer (Calbiochem) containing Complete protease
inhibitor cocktail prior to IP for TSG101. Proteinswere separated bySDS-
PAGE and transferred to Immobilon P membrane (Millipore, Billerica,
MA) for immunoblotting. All data shown is representativeof at least two
independent experiments. Antibodies used: MGRN1 (#11285-1-AP,
ProteinTech Group, Inc., Chicago, IL), TSG101 (#612696, BD Biosciences,
San Jose, CA or #C-2, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), HA
(#MMS-101P, Covance, Trenton, NJ), GFP (#JL-8, Clontech or
#MAB3580, Millipore), Myc (#Ab32, Abcam, Cambridge, MA) and
GAPDH (#Ab9482, Abcam). For IB of TSG101 on MGRN1 IP products,
Clean-Blot DetectionReagent (ThermoScientiﬁc, Rockford, IL)was used
in place of a secondary antibody to avoid the heavy chain IgG band that
is very close in size to TSG101.
2.3. Western analysis of mouse tissues
For analysis of TSG101 expression, brains were rapidly dissected
from at least 2 animals of each genotype, then homogenized in aFig. 2. A conserved PSAP motif in MGRN1 mediates its association with TSG101. (A) Verteb
protein, MGRN2 (RNF157) or invertebrate MGRN homologs. (B) HEK293T cells were transfe
mutantMGRN1(ASAA)-GFP (PSAPmotifmutated toASAA). Lysateswere subjected to IP using
coimmunoprecipitated with TSG101, indicating that the PSAP motif is required for their ass
MGRN1 and MGRN2. MGRN2 does not contain a PSAP motif.Dounce homogenizer on ice in RIPA buffer (50mM Tris, 150 mMNaCl,
1%w/v Triton X-100) containing Complete protease inhibitor cocktail.
For solubility assay, brains were homogenized in Triton X-100 buffer
(50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) with
Complete protease inhibitor cocktail using a TissueLyser (Qiagen,
Valencia, CA). The homogenate was centrifuged at 15,000g for 20 min
at 4 °C, and the supernatant collected as the detergent-soluble
fraction. The resulting pellet was washed three times in Triton X-100
buffer then homogenized in Triton X-100 buffer supplemented with
2% SDS to collect the detergent-insoluble fraction. Protein concentra-
tions were determined using BCA Protein Assay (Thermo Scientiﬁc)
and 50 μg of protein separated by SDS-PAGE (10% w/v acrylamide).
Proteins were transferred to Immobilon P membrane and immuno-
blotted using anti-TSG101 antibody (#C-2, Santa Cruz). Blots were
stripped and reblotted for GAPDH to verify equal protein loading.
RIPA-extracted brain proteins from wild-type and Mgrn1md-nc/md-nc
mice were also subjected to IP for TSG101 (as described above) and
blotted for TSG101 and ubiquitin (FK2 (#PW0150), Biomol Inter-
national Inc., Plymouth Meeting, PA) to conﬁrm that the high-
molecularweight bands observedwith the TSG101 antibody represent
multiubiquitinated TSG101.
2.4. Viral budding assay
HEK293T cells were plated in 12-well tissue culture dishes at a
density of 5×105 cells/well in 1 mL DMEM (Cellgro) supplemented
with 10% FBS and L-glutamine. The following day, each well was
transfected with 0.5 μg of HIV-1 GAG [42] and 1.0 μg of either GFP,
GFP-VPS4(EQ) [43], wild-type MGRN1-GFP or MGRN1(AVVA)-GFP
plasmids (“treatments”), using 3 μl Lipofectamine 2000 (Invitrogen)
per well. HIV-1 GAG and VPS4(EQ) plasmids were generously
provided by Dr. Volker Vogt. Transfection efﬁciency was monitored
by GFP ﬂuorescence and estimated to be equivalent (∼60%) for all
samples. Twenty-four hours post-transfection, media was collected
and spun at 2000 rpm for 1 min to pellet debris. Cleared media was
spun at 13,000 rpm in a microcentrifuge for 100 min to pellet virus-
like particles (VLPs), which were resuspended in 1× sample loading
buffer (60 mM Tris–HCl, pH 6.8, 5% glycerol, 3% SDS, 1 M BME, 0.025%rate MGRN1 homologs contain a PSAP “late-viral” motif that is not found in the related
cted with Myc-tagged TSG101 and control GFP, MGRN2-GFP, wild-type MGRN1-GFP, or
an antibody againstMyc (to IP TSG101) and blotted for GFP. Onlywild-typeMGRN1-GFP
ociation. (C) Schematic showing protein structures of and amino acid identity between
1030 J. Jiao et al. / Biochimica et Biophysica Acta 1792 (2009) 1027–1035bromophenol blue) and boiled (95 °C for 5 min) for western analysis.
Cells were collected into lysis buffer (50 mM Tris–HCl pH 8.0, 1%
Igepal CA-630, 1 mM EDTA, 10 mM iodoacetamide with Complete
protease inhibitor cocktail), incubated on ice for 15 min, and
centrifuged at 13000 rpm for 10 min. Supernatants in sample loading
buffer were boiled as for VLP preps. Samples (∼20% of total for VLP
preparations, ∼3% of total for cell lysates) were separated on 10%
polyacrylamide gels under standard Laemmli conditions and electro-
phoretically transferred to Immobilon P membrane (Millipore).Fig. 3.MGRN1 multimonoubiquitinates TSG101. (A) MGRN1 ubiquitinates TSG101. Duplicat
treated with proteasome inhibitor MG132 prior to collection of lysates. Lysates were subjec
treatment, TSG101 was multiubiquitinated in cells expressing empty GFP vector or wild-
ubiquitinated TSG101 was detected in cells expressing catalytically inactive MGRN1 (MGRN1
ubiquitination. HEK293T cells were transfected with indicated amounts (μg) of each plasm
(control for protein loading). A smear of ubiquitinated TSG101 was detected in cells expres
intensity of the signal for multiubiquitinated TSG101 (Myc-TSG101-(Ub)n) was much re
multimonoubiquitinates TSG101. HEK293T cells were transfected with indicated plasmids a
detect ubiquitin-K0 (contains no lysine residues to allow for the formation of polyubiquitin
overexpressing MGRN1. Lysates were blotted for HA (to detect HA-MGRN1; HA produced fr
HEK293T cells were transfected with indicated plasmids. Lysates were subjected to IP for G
MGRN1 (AVVAmutant) not only still binds TSG101, but binds it more tightly than wild-type
in the IP lane from cells expressing MGRN1(AVVA)-GFP.Immunoblotting was performed under standard conditions, using
rabbit anti-HIV CA polyclonal antibody (HIV-1SF2 p24 Antiserum, NIH
AIDS Research and Reference Reagent Program #4350). Blots were
visualized using a VersaDoc 5000 (BioRad). Each gel contained one set
of samples for each treatment. Band intensities were quantiﬁed using
Quantity One software (BioRad), correcting for background using the
signal from a lane for a sample prepared from cells transfected only
with GFP vector (no GAG DNA). Samples on the same gel/blot were
compared to one another to control for inter-blot variability. Thee sets of HEK293T cells were transfected with indicated plasmids. One set of plates was
ted to IP for endogenous TSG101 and blotted for HA (ubiquitin). Regardless of MG132
type MGRN1-GFP, with a stronger signal in cells overexpressing MGRN1. Very little
(AVVA)-GFP) or siRNA againstMgrn1. (B) Dose-dependent effect of MGRN1 on TSG101
id. Lysates were blotted for Myc (TSG101), GFP (GFP or tagged MGRN1) and GAPDH
sing MGRN1, with a stronger signal in cells expressing higher amounts of MGRN1. The
duced in cells expressing catalytically inactive MGRN1 (AVVA mutant). (C) MGRN1
nd lysates subjected to IP for endogenous TSG101. IP products were blotted for GFP to
chains). A signiﬁcant increase in multimonoubiquitinated TSG101 was observed in cells
om empty vector ran off the bottom of the gel) and TSG101 to conﬁrm expression. (D)
FP (MGRN1) and blotted for Myc (TSG101) to demonstrate that catalytically inactive
MGRN1: Myc-TSG101 expression was equal in the lysates prior to IP but much stronger
Fig. 4. Age- and MGRN1-dependent changes in TSG101 ubiquitination in the mouse
brain. (A) Immunoblotting (IB) of whole brain protein lysates from wild-type (wt),
Mgrn1 heterozygous (het) and Mgrn1 null mutant mice for TSG101. In wild-type
mice, high levels of multiubiquitinated TSG101 (TSG101-(Ub)n) were observed in
lysates from 1-month-old animals, but most TSG101 expression in older (3-month-old)
animals was unmodiﬁed or monoubiquitinated. At 1-month of age, the levels of
multiubiquitinated TSG101 were lower in Mgrn1 null mutant brains than in wild-type
brains, but at 3-months of age, there was moremultiubiquitinated TSG101 in the brains
of mutant mice. At both ages, heterozygotes had levels intermediate to those of null
mutants and wild-type mice. A 3-min exposure is shown for 1 month samples, a 1-min
exposure for 3-month samples (3-min exposure of both shown in Supplemental Fig.
S3B). Multiubiquitinated TSG101 was observed in samples from 3-month-old mice
when blots were imaged longer (not shown). (B) Brain lysates from 6-month-old wild-
type (wt) andMgrn1 null mutant mice were subjected to IP for TSG101. Duplicate blots
were immunoblotted for TSG101 and ubiquitin (FK2 antibody, which recognizes mono-
and poly-ubiquitinated proteins), respectively. Both antibodies detected the same high
molecular weight bands, indicating that they represent multiubiquitinated TSG101.
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media to GAG signal in cell lysates for each transfection relative to that
of the GAG+GFP (control) samples run on the same blot. Differences
between the relative budding index value of each treatment and the
GFP control were assessed using a pairwise 2-tailed Student's T-test.
3. Results
3.1. MGRN1 associates with TSG101
Yeast two-hybrid screens using the region of MGRN1 C-terminal to
the RING domain yielded several partial Tsg101 cDNA clones as strong
interactors (Fig. 1A). We conﬁrmed that MGRN1 associated with
TSG101 in mammalian cells by several means, including coIP of
endogenous MGRN1 and TSG101 from untransfected HEK293T cells
(Fig. 1B). All of the Tsg101 cDNA clones isolated from yeast-two
hybrid screens contained sequences encoding the N-terminal ubiqui-
tin E2 variant (UEV) domain (Fig. 1A). Some clones extended further
C-terminal into the adjacent proline-rich domain (PRD) and/or coiled
coil (CC) region. Analysis of theMGRN1 amino acid sequence revealed
a PSAP motif that is highly conserved among vertebrate MGRN1
homologs (Fig. 2A). This motif is found in all vertebrate MGRN1
isoforms. Interestingly, bovine MGRN1 contains a short replacement
of sequence that disrupts the PSAP motif but replaces it with a
functionally interchangeable PTAP sequence (Fig. 2A). P[S/T]AP
motifs are considered “late viral domains” and the UEV domain of
TSG101 has previously been shown to interact with this motif in a
variety of proteins including HRS, several viral GAG proteins and the
TAL ubiquitin ligase [31,44–46]. To test whether the PSAP motif of
mouse MGRN1 mediates its association with TSG101, site-directed
mutagenesis was performed to convert it to ASAA (MGRN1(ASAA)-
GFP). CoIP and immunoblotting assays conﬁrmed that MGRN1
(ASAA)-GFP did not associate with TSG101 (Fig. 2B).
Neither Drosophila, sea squirt nor worm MGRN proteins contain a
P[S/T]AP motif (Fig. 2A), suggesting that association between MGRN1
and TSG101 is a relatively recent evolutionary event. Vertebrates
contain a homologous gene, Mgrn2 (Rnf157), that encodes a C3HC4
RING-containing protein 69% identical to MGRN1 (Fig. 2C). MGRN2,
like invertebrate MGRN homologs, lacks a P[S/T]AP motif (Fig. 2A,C).
MGRN1 and MGRN2 are most similar across the region N-terminal to
the location of the PSAP motif in MGRN1 (Fig. 2C). We transiently
transfected HEK293T cells with GFP-tagged MGRN2 and Myc-tagged
TSG101 expression constructs and used IP and IB to conﬁrm that
MGRN2 did not associate with TSG101 (Fig. 2B).
3.2. MGRN1 multimonoubiquitinates TSG101
Association of MGRN1with TSG101 suggested that TSG101may be
a target for MGRN1-mediated ubiquitination. To test this hypothesis,
HEK293T cells were transfected with HA-ubiquitin and either empty
GFP vector, MGRN1-GFP, catalytically inactive MGRN1(AVVA)-GFP, or
siRNA against Mgrn1. In the presence or absence of the proteasome
inhibitor MG132, multiubiquitination of TSG101 was increased in
MGRN1-GFP transfected cells relative to vector-transfected cells
(which contain endogenous MGRN1) and greatly reduced in cells
expressing MGRN1(AVVA)-GFP or Mgrn1 siRNA (Fig. 3A, B). A short
exposure of Fig. 3A shows that more multiubiquitinated TSG101 is
present in cells expressing MGRN1-GFP than GFP alone, even in the
presence of the proteasome inhibitor MG132 (Fig. S2 in the
supplementary material). Experiments using GFP-ubiquitin-K0 (in
which all lysines have been mutated to alanines, rendering it
incapable of forming polyubiquitin chains) in place of wild-type
ubiquitin showed a similar pattern of MGRN1-dependent ubiquitina-
tion of TSG101, indicating that TSG101 is multimonoubiquitinated by
MGRN1 (Fig. 3C). We conﬁrmed that MGRN1(AVVA)-GFP was still
able to associate with TSG101; in fact, TSG101 appeared to associatemore strongly withMGRN1(AVVA)-GFP thanwith wild-typeMGRN1-
GFP (Fig. 3D). Catalytically inactive mutants of other E3s have also
been shown to bind their target proteins more strongly [i.e., 47].
3.3. MGRN1 regulates TSG101 in the mouse brain
As our primary interest was whether loss of MGRN1-mediated
ubiquitination of TSG101 contributes to the development of spongi-
form neurodegeneration inMgrn1 null mutant mice, we used western
analysis to examine TSG101 expression in brain protein extracts from
wild-type, Mgrn1 heterozygotes and Mgrn1 null mutant mice
(Figs. 4A and S3 in the supplementary material). Several TSG101
bands were observed, consistent with unmodiﬁed (∼44 kDa) and
post-translationally modiﬁed forms, with the latter being consistent
in size with bands described by others as ubiquitinated TSG101. We
conﬁrmed that the high molecular weight bands represented
ubiquitinated forms of TSG101 by immunoprecipitating TSG101
from brain lysates and showing that these bands were detected
with antibodies against TSG101 and ubiquitin (Fig. 4B). As we did not
distinguish whether they represent multimono- or poly-ubiqutinated
TSG101, or both, these bands will be referred to as multiubiquitinated
TSG101.
More multiubiquitinated TSG101 was observed in brain lysates
from 1-month-old mice than from 3- and 6-month-old wild-type
mice (Figs. 4A and S3 in the supplementary material), although high
molecular weight forms of TSG101 were detected in samples from
older animals when blots were imaged longer (or following IP for
TSG101, as shown in Fig. 4B). Multiubiquitinated TSG101 was present
Fig. 5. EGFR, which requires functional TSG101 for its endosomal transport to the
lysosome to be degraded, accumulates in the brains of Mgrn1 null mutant mice. Brain
protein lysates from wild-type (wt) and Mgrn1 null mutant animals of the indicated
ages were subjected to IB for EGFR. Protein loading is indicated by IB for GAPDH.
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andMgrn1 null mutant mice relative to controls. In 3- or 6-month-old
animals, however, the bands representing multiubiquitinated TSG101
were stronger in the brains of heterozygotes and Mgrn1 null mutant
mice than in wild-type animals and than in 1-month old hetero-
zygotes andMgrn1 null mutants (Figs. 4A and S3B). A band consistent
in size with monoubiquitinated TSG101 was present in brain lysates
from 3- and 6-month-old wild-type mice but not in 1-month-old
wild-type mice nor in Mgrn1md-nc/+ or Mgrn1md-nc/md-nc mice at any
of the ages examined. At all ages, differences in the levels of TSG101
and its modiﬁed forms were associated with the number of functional
Mgrn1 alleles, where samples from heterozygotes had levels inter-
mediate to those from wild-type and Mgrn1 null mutant mice.
TSG101 plays a crucial role in sorting monoubiquitinated proteins,
such as the epidermal growth factor receptor (EGFR), into MVBs to
trafﬁc them to the lysosome for degradation. If TSG101 function is
impaired in the brains of Mgrn1 null mutant mice, EGFR trafﬁcking
would be expected to be disrupted. Western blotting demonstrated a
signiﬁcant increase in EGFR levels in the brains of 1-month-oldMgrn1
null mutant mice relative to wild-type mice (Fig. 5). There was also a
slight increase in EGFR levels in the brains of 6-month-oldMgrn1 null
mutant mice (Fig. 5).
TAL-dependent ubiquitination of TSG101 has previously been
reported to increase TSG101 solubility [44]. Since loss of MGRN1 led to
the accumulation of ubiquitinated TSG101 in the brains of 3-month-
old (and older) Mgrn1 null mutant mice, we examined whether the
solubility of TSG101 also changed with age or was affected by loss ofFig. 6. Loss of MGRN1 results in the accumulation of insoluble, high molecular weight (mult
month-old wild-type (wt) andMgrn1 null mutant mice was performed to isolate proteins ba
SDS fractions). Fractions were subjected to IB to detect unmodiﬁed and ubiquitinated TSG
(bottom panels), and blotted for GAPDH as a loading control. In the brains of young animal
animals, multiubiquitinated TSG101 was observed in both fractions, although more was prMGRN1. Brain proteins from 1- and 6-month-old Mgrn1 null mutant
and wild-type mice were extracted in Triton X-100 buffer and the
resulting pellet extracted with SDS-containing buffer. Immuno-
blotting for TSG101 demonstrated that very little of the multi-
ubiquitinated TSG101 in 1-month-old wild-type brains was soluble in
Triton X-100 while a greater proportion was soluble in 6-month-old
wild-type brains (Fig. 6). Most TSG101 in the brains of 1-month-old
Mgrn1 null mutants was not ubiquitinated and was soluble in Triton
X-100. Therewas a signiﬁcant increase in soluble and insoluble TSG101
in the brains of 6-month-oldMgrn1 null mutants, with the majority of
insoluble TSG101 being ubiquitinated in those samples (Fig. 6). Thus,
upon prolonged absence of MGRN1 from the mouse brain, most of the
multiubiquitinated TSG101 that accumulates is insoluble.
3.4. MGRN1 is not required for viral budding
We examined the release of HIV-1 GAG from cells to test whether
MGRN1-dependent ubiquitination of TSG101 was also required for
VLP budding. HEK293T cells were mock-transfected or transfected
with HIV-1 GAG and either a mutant VPS4 that disrupts viral budding
(GFP-VPS4(EQ)), empty GFP vector, wild-type MGRN1-GFP or
catalytically inactive MGRN1 (MGRN1(AVVA)-GFP). GAG release
from cells as VLPs was detected by IB for GAG on proteins extracted
from the cell media, while GAG retained in the cells was detected by IB
for GAG on cell lysates. The budding indexwas determined as the ratio
of secreted GAG/intracellular GAG in treated samples relative to
control (GAG+GFP), averaged over 3 experiments. While the VPS4
(EQ) mutant greatly diminished GAG release, as expected, the
addition of excess wild-type or catalytically inactive MGRN1 had no
signiﬁcant effect (Fig. 7A, B). This suggests that the effect of MGRN1-
dependent ubiquitination on TSG101 function may be restricted to
endo-lysosomal trafﬁcking.
4. Discussion
TSG101 is a highly conserved and essential protein required for
sorting ubiquitinated cargo to the inner vesicles of MVBs. Here, we
conﬁrm and extend the work of Kim et al. [40], showing that the
vertebrate-speciﬁc E3 ubiquitin ligase MGRN1 binds and multi-
monoubiquitinates TSG101 to regulate its function in endo-lysosomal
trafﬁcking in vivo. We focused on the effect of loss of MGRN1 in theiubiquitinated) forms of TSG101. Sequential extraction of brain proteins from 1- and 6-
sed on their solubility (proteins in Triton X-100 fractions are more soluble than those in
101 (TSG101-(Ub)n). The same blots were imaged for 1 min (top panels) and 10 min
s, multiubiquitinated TSG101 was predominantly observed in the SDS fraction. In older
esent in the SDS fraction in the brains of Mgrn1 null mutants than in wild-type mice.
Fig. 7. Overexpression of neither wild-type nor catalytically inactive MGRN1
signiﬁcantly affects HIV-1 GAG release from cells. HEK293T cells were cotransfected
with an HIV-1 GAG p55 expression construct and either a GFP control, a positive control
for budding inhibition (GFP-VPS4(EQ)), or GFP fusion constructs expressing wild-type
MGRN1 or catalytically inactive MGRN1 (AVVA mutant). (A) Representative immuno-
blots from 1 of 3 replicate experiments. Top panel: GAG IB of virus-like particle (VLP)
preps frommedia of transfected cells. Middle panel: GAG IB of cell lysates of transfected
cells. Bottom panel: non-speciﬁc bands from upper region of cell lysate blot
demonstrate even loading. (B) Graphical representation of the effect of each treatment
on VLP budding, averaged from 3 replicate experiments. Relative budding index (y axis)
represents the ratio of GAG signal in VLPs to GAG signal in cell lysates of each
transfection relative to that of GAG+GFP control samples. VPS4(EQ) reduced GAG
release (pb0.02) while neither wild-type nor catalytically inactive MGRN1 had a
signiﬁcant effect (pN0.3). The standard error of the GAG+GFP transfected samples is 0
because the budding index of these samples is deﬁned as 1 within each experiment.
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between Mgrn1 genotype and levels of multiubiquitinated TSG101
(which was lower in homozygous null mutants than in hetero-
zygotes) indicates that MGRN1 is responsible for ubiquitinating a
signiﬁcant portion of TSG101 in the brains of young (1-month-old)
wild-type mice. The PSAP motif in MGRN1 that mediates its
association with TSG101 is not present in invertebrate MGRN
homologs, nor in the vertebrate family member MGRN2 (RNF157).
This implies that the ability of MGRN1 to associate with TSG101 is a
relatively recent evolutionary event and either has an important
vertebrate-speciﬁc function or plays a role in vertebrate cells that is
performed by another E3 ligase in non-vertebrates. We also observed
age-dependent changes in the pattern of TSG101 expression in the
brains of wild-typemice, withmore TSG101multiubiquitinated in the
brains of young (1-month-old) animals than in adult mice. This
suggests that MGRN1-dependent TSG101-mediated endocytic
trafﬁcking may be particularly important during development and
that only low levels of activity are required for normal adult CNS
function.
The fact that ubiquitinated TSG101 is reduced but not absent in the
brains of young Mgrn1 null mutant mice indicates that MGRN1 is not
the only E3 ligase that targets TSG101 at this age. The accumulation ofmultiubiquitinated TSG101 in the brains of older animals that lack
MGRN1 suggests that, upon prolonged absence or reduction of
MGRN1, TSG101 is recognized and ubiquitinated by another E3. At
least two other E3s, MDM2 and TAL (also known as LRSAM1), have
been reported to ubiquitinate TSG101 [44,45,48,49]. TAL has been
reported to multimonoubiquitinate TSG101 to regulate its cargo-
sorting and viral budding functions [44], and to polyubiquitinate
TSG101 and target it for proteasomal degradation when it is not part
of the ESCRT complex [45]. TAL, like MGRN1, is not found in
invertebrates. This suggests multiple changes in the regulation of
TSG101 during vertebrate evolution.
Interestingly, TAL and MGRN1 have different effects on the viral
budding and EGFR trafﬁcking functions of TSG101: knock-down of
TAL expression by siRNA increased VLP release; overexpression of
wild-type TAL increased EGFR levels and inhibited VLP (GAG) release;
and overexpression of catalytically inactive TAL reduced EGFR levels
[44]. Overexpression of MGRN1 had no effect on GAG budding and
loss of MGRN1 resulted in elevated levels of EGFR. TAL-mediated
ubiquitination of TSG101 increased its solubility [44]. Since the
solubility of the ubiquitinated TSG101 that accumulates in the brains
of Mgrn1 null mutant mice was reduced, TAL is probably not the E3
that ubiquitinates TSG101 in the brains of older animals lacking
MGRN1. The fact that multiubiquitinated TSG101 accumulates in the
brains of adultMgrn1 null mutantmice indicates that it is not targeted
for proteasomal degradation, while its reduced solubility suggests
that it may form insoluble cytoplasmic aggregates or be membrane-
bound. If the latter, multimonoubiquitination by MGRN1 may be
necessary for TSG101 to complete its ESCRT-I function and subse-
quently be released from endosomal membranes. The increase in
EGFR levels in the brains ofMgrn1 null mutant mice is consistent with
MGRN1-dependent ubiquitination of TSG101 being required for its
normal function in MVB sorting and receptor down-regulation.
While further studies will be needed to determine whether
disrupted TSG101 function in fact causes the spongiform neuro-
degeneration observed in Mgrn1 null mutant mice, there are at least
two possible mechanisms by which it could do so. The ﬁrst is related
to the fact that endo-lysosomal trafﬁcking of EGFR is required for its
down-regulation and degradation in the lysosome [50–52]. We
observed increased levels of EGFR in the brains of Mgrn1 null mutant
mice, particularly in 1-month-old animals. Lysosomal trafﬁcking of
EGFR has also been reported to be disrupted in cells in which MGRN1
was depleted by siRNA, with prolonged activation of mitogen-
activated protein (MAP) kinase signaling [40]. Exposure of mixed
cortical cultures (containing neurons and astrocytes) to 100 ng/ml of
EGF caused neuronal death associated with features of necrosis and
increased free radical generation [53]. The EGFR-speciﬁc tyrosine
kinase inhibitor C56 blocked the effect of excess EGF, indicating that
the neurotoxicity was mediated through EGFR signaling. Thus,
accumulation of activated EGFR could be responsible for (or at least
contribute to) elevated levels of oxidatively damaged proteins
observed in the brains ofMgrn1 null mutantmice [37] and subsequent
vacuolation.
Another possibility is that the vacuoles in the brains of Mgrn1
null mutant mice represent accumulated endocytic compartments.
Mammalian cells lacking TSG101 showed disrupted bulk transport to
the lysosome as well as structural rearrangement of the early
endosome to form enlarged vacuoles that were often folded into
multicisternal structures reminiscent of the abnormal membranous
compartments that accumulate in yeast “Class E” vacuolar protein
sorting (vps) mutants [54,55]. We propose that any mutation that
severely disrupts endo-lysosomal trafﬁcking would cause the
accumulation of endocytic compartments that could, over time,
enlarge to ﬁll the cell. Loss-of-function mutations in Fab1 (endo-
somal phosphatidylinositol PtdIns(3)P 5-kinase) in Drosophila or
Vac14 (a regulator of phosphatidylinositol-3,5-bisphosphate (PtdIns
(3,5)P2) synthesis) or Fig4 (a PtdIns(3,5)P2 5-phosphatase) in mice
1034 J. Jiao et al. / Biochimica et Biophysica Acta 1792 (2009) 1027–1035have also been shown to disrupt endo-lysosomal trafﬁcking and cause
cellular vacuolation and spongiform neurodegeneration [9,10,17,56].
Thus, defects in intracellular trafﬁcking represent a common cellular
mechanism for causing spongiform neurodegeneration. It remains to
be determined whether vacuoles are the result of aberrant trafﬁcking
of and signaling by speciﬁc receptors, the accumulation of endosomal
compartments, or a combination of the two.
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